IRIS
DRAGONI, FILIPPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.547
NA - Nord America 2.397
AS - Asia 1.283
SA - Sud America 250
AF - Africa 118
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.615
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.337
RU - Federazione Russa 626
IT - Italia 583
SG - Singapore 363
IE - Irlanda 355
GB - Regno Unito 353
CN - Cina 264
BR - Brasile 212
VN - Vietnam 160
DE - Germania 143
FR - Francia 134
HK - Hong Kong 133
SE - Svezia 133
IN - India 97
FI - Finlandia 58
PK - Pakistan 48
ZA - Sudafrica 47
KR - Corea 44
BD - Bangladesh 42
CA - Canada 33
ES - Italia 29
JP - Giappone 24
PL - Polonia 23
NG - Nigeria 22
UA - Ucraina 20
TR - Turchia 19
AU - Australia 16
MX - Messico 15
IR - Iran 14
AT - Austria 11
IQ - Iraq 11
NL - Olanda 11
BE - Belgio 10
AR - Argentina 9
EG - Egitto 9
ID - Indonesia 8
MA - Marocco 8
TW - Taiwan 8
DK - Danimarca 7
GH - Ghana 7
HU - Ungheria 7
UZ - Uzbekistan 7
CZ - Repubblica Ceca 6
DZ - Algeria 6
EC - Ecuador 6
GR - Grecia 6
KE - Kenya 6
PY - Paraguay 6
VE - Venezuela 6
LV - Lettonia 5
MY - Malesia 5
NP - Nepal 5
CI - Costa d'Avorio 4
CL - Cile 4
CY - Cipro 4
HN - Honduras 4
NO - Norvegia 4
PT - Portogallo 4
TH - Thailandia 4
AZ - Azerbaigian 3
JM - Giamaica 3
JO - Giordania 3
NZ - Nuova Zelanda 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
CO - Colombia 2
CR - Costa Rica 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
IL - Israele 2
LK - Sri Lanka 2
LT - Lituania 2
RO - Romania 2
SN - Senegal 2
TN - Tunisia 2
TZ - Tanzania 2
BA - Bosnia-Erzegovina 1
DO - Repubblica Dominicana 1
EU - Europa 1
GT - Guatemala 1
GY - Guiana 1
IM - Isola di Man 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
ML - Mali 1
MN - Mongolia 1
PA - Panama 1
PE - Perù 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
Totale 6.613
Salva come PNG Salva come JPEG
Città #
Dublin 352
Southend 278
Dallas 275
Chandler 203
Singapore 202
Ashburn 171
Moscow 167
San Jose 156
Santa Clara 154
Fairfield 144
Hong Kong 121
Milan 118
Siena 107
Beijing 80
Council Bluffs 77
New York 68
Seattle 63
Munich 59
Rome 54
Los Angeles 52
Houston 51
Woodbridge 50
Ho Chi Minh City 48
Princeton 48
Cambridge 47
Hefei 42
Johannesburg 42
Lauterbourg 38
Wilmington 38
Seoul 36
Hanoi 35
Helsinki 34
Ann Arbor 26
Orem 24
São Paulo 24
Bengaluru 21
The Dalles 19
Málaga 18
Tokyo 18
Dong Ket 17
Frankfurt am Main 17
Shanghai 17
Boardman 16
Florence 16
Jacksonville 16
London 16
Redondo Beach 16
Warsaw 16
Chennai 15
Buffalo 14
Portsmouth 14
Chicago 13
Montreal 13
Atlanta 12
San Diego 12
Turku 12
Abuja 11
San Mateo 11
Brussels 10
Düsseldorf 10
Nuremberg 10
San Francisco 10
Toronto 10
Brescia 9
Brisbane 9
Brooklyn 9
Dearborn 9
Fremont 9
Islamabad 9
Lappeenranta 9
Multan 9
Naples 9
Perugia 9
Figino 8
Mexico City 8
Mumbai 8
Poplar 8
Belo Horizonte 7
Cairo 7
Da Nang 7
Denver 7
Divinópolis 7
Haiphong 7
Karachi 7
Lagos 7
Lahore 7
Phoenix 7
Rawalpindi 7
Roccagorga 7
São José do Rio Preto 7
Turin 7
Amsterdam 6
Guangzhou 6
Jaipur 6
Manchester 6
Paris 6
Pécs 6
Rio de Janeiro 6
Tashkent 6
Vienna 6
Totale 4.158
Salva come PNG Salva come JPEG
Nome #
Antiviral drug development for treatment of acute and chronic viral infections 592
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 303
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 300
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 297
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 259
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 256
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 255
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 252
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 238
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 205
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 202
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 194
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 185
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 185
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 185
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 184
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 172
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 172
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 167
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 165
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 160
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 145
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 145
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 143
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 141
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 140
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 140
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 134
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected 126
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 125
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 124
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 118
Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia 112
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 111
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 64
null 32
null 14
Totale 6.742
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022595 28 59 46 66 40 37 44 36 38 43 57 101
2022/2023652 41 89 72 55 54 121 38 50 39 34 29 30
2023/2024601 20 21 54 37 4 165 197 18 0 11 31 43
2024/20251.287 36 43 192 67 127 98 52 100 111 96 120 245
2025/20262.861 180 313 250 382 624 99 292 101 129 163 113 215
2026/202733 33 0 0 0 0 0 0 0 0 0 0 0
Totale 6.742